Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity

被引:3
|
作者
Medipally, Ajay [1 ]
Xiao, Min [1 ]
Biederman, Laura [1 ]
Satoskar, Anjali A. [1 ]
Ivanov, Iouri [1 ]
Rovin, Brad [2 ]
Parikh, Samir [2 ]
Kerlin, Bryce A. [3 ,4 ]
Brodsky, Sergey, V [1 ]
机构
[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA
[4] Nationwide Childrens Hosp, Ctr Clin & Translat Res, Abigail Wexner Res Inst, Columbus, OH USA
来源
PHYSIOLOGICAL REPORTS | 2022年 / 10卷 / 15期
关键词
anticoagulant related nephropathy; glomerular filtration barrier; PAR-1; renal pathology; ACUTE KIDNEY INJURY; WARFARIN; NEPHROPATHY; COAGULATION; PROTECTION; MODEL;
D O I
10.14814/phy2.15343
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Protease-activated receptors (PAR) play an important role in the regulation of cellular function by the coagulation system, and they are activated by thrombin. PAR-1 is expressed in both endothelial cells and podocytes in the kidney. The role of PAR1 in the maintenance of the glomerular filtration barrier is not clear. Anticoagulant-related nephropathy (ARN) is a kidney disease with glomerular hematuria and red blood cell tubular casts. We validated 5/6 nephrectomy (5/6NE) in rats as a model of ARN and had demonstrated that direct thrombin inhibitor (dabigatran) induces ARN. The aim of this study was to investigate the role of PAR-1 in the ARN pathogenesis. 5/6NE rats were treated with dabigatran (150 mg/kg/day), PAR-1 inhibitor SCH79797 (1 and 3 mg/kg/day) and PAR-1 agonist TFLLR-NH2 (0.25 and 0.50 mu mol/kg/day) for 7 days. Serum creatinine and hematuria were assessed daily. Kidney morphology was evaluated at the end of the study. In 5/6NE rats treated with either dabigatran or combination with a PAR-1 modulator, there was an elevation in serum creatinine, glomerular hematuria, red blood casts in the tubules, and acute tubular epithelial cell injury. Interestingly, both PAR-1 modulators in a dose-depended manner had similar effects on the serum creatinine levels and hematuria as those of dabigatran. Dabigatran-induced increase in the systolic blood pressure was not affected by PAR-1 modulators. In conclusion, the normal function of PAR-1 is crucial to maintain the glomerular filtration barrier integrity. Either activation or blockage of PAR-1 leads to glomerular hematuria and subsequent acute tubular epithelial cell injury.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Protease-activated receptor-1 (PAR-1) increases intracellular calcium and mediates chloride secretion in an epithelial cell line
    Buresi, MC
    Schleihauf, E
    Vergnolle, N
    Chapman, K
    Buret, A
    Wallace, JL
    Hollenberg, MD
    MacNaughton, WK
    FASEB JOURNAL, 2000, 14 (04): : A114 - A114
  • [22] Protease-activated receptor-1 at the synapse
    Shavit-Stein, E.
    Katzev, A.
    Chapman, J.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 45 (SUPPL 1) : S108 - S108
  • [23] Suppression of ischaemia-induced injuries in rat brain by protease-activated receptor-1 (PAR-1) activating peptide
    Zhen, Xia
    Ng, Ethel Sau Kuen
    Lam, Francis Fu Yuen
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 786 : 36 - 46
  • [24] Protease-Activated Receptor (par)-2 Is Required For Par-1 Signaling In Pulmonary Fibrosis
    Lin, C.
    Aberson, H. L.
    Von der Thusen, J.
    Borensztajn, K.
    Spek, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [25] Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis
    Lin, Cong
    von der Thusen, Jan
    Daalhuisen, Joost
    ten Brink, Marieke
    Crestani, Bruno
    van der Poll, Tom
    Borensztajn, Keren
    Spek, C. Arnold
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2015, 19 (06) : 1346 - 1356
  • [26] Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer
    Fujimoto, Daisuke
    Hirono, Yasuo
    Goi, Takanori
    Katayama, Kanji
    Yamaguchi, Akio
    ANTICANCER RESEARCH, 2008, 28 (2A) : 847 - 854
  • [27] Membrane lipid peroxidation (MLP) in Alzheimer's (AD) and Parkinson's (PD) brains and role of protease-activated receptor-1 (PAR-1).
    Ameenuddin, JS
    Landis, M
    SantaCruz, KS
    Festoff, BW
    JOURNAL OF NEUROCHEMISTRY, 2000, 74 : S17 - S17
  • [28] Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1
    Schuepbach, Reto A.
    Feistritzer, Clemens
    Fernandez, Jose A.
    Griffin, John H.
    Riewald, Matthias
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 724 - 733
  • [29] Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats
    Andrade-Gordon, P
    Derian, CK
    Maryanoff, BE
    Zhang, HC
    Addo, MF
    Cheung, WM
    Damiano, BP
    D'Andrea, MR
    Darrow, AL
    De Garavilla, L
    Eckardt, AJ
    Giardino, EC
    Haertlein, BJ
    McComsey, DF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298 (01): : 34 - 42
  • [30] The role of protease activated receptor-1 (PAR-1) in tumor invasion and metastasis, angiogenesis, and mammary gland morphogenesis
    Salah, Z
    Yin, YJ
    Maoz, M
    Cohen, I
    Uziely, B
    Grisaru-Granovsky, S
    Bar-Shavit, R
    PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON TUMOR MICROENVIRONMENT PROGRESSION, THERAPY & PREVENTION, 2002, : 133 - 139